Clonality, Mutation and Kaposi Sarcoma: A Systematic Review

Blanca Iciar Indave Ruiz1, Subasri Armon1, Reiko Watanabe1

  • 1International Agency for Research on Cancer (IARC), World Health Organization, 69372 Lyon, France.

Cancers
|March 10, 2022
PubMed
Abstract

Insights

Kaposi sarcoma (KS) may produce tumors, but evidence is insufficient to classify it as a clonal neoplasm. Further research is needed to determine if KS is a virus-driven lesion or a true sarcoma.

Area of Science:

  • Oncology
  • Virology
  • Genetics

Background:

  • Kaposi sarcoma (KS) etiology is debated, particularly its classification as a neoplasm.
  • Uncertainty exists regarding KS regression upon removal of Human Herpesvirus 8 (HHV-8) stimulus and reduced immunosuppression.

Purpose of the Study:

  • To evaluate the available evidence on somatic mutations and clonality in KS.
  • To determine if KS exhibits characteristics of a neoplasm.

Main Methods:

  • Systematic literature search of Medline and Web of Science up to September 2020.
  • Independent study selection and data extraction by two researchers.
  • Methodological quality appraisal using an adapted QUADAS-2 tool.

Main Results:

  • Twenty publications were eligible for qualitative synthesis from 3077 identified records.
  • Studies reported on clonality (5), mutations (10), and chromosomal aberrations (5) in KS.
  • High risk of bias and considerable heterogeneity in results were noted across studies.

Conclusions:

  • KS exhibits tumor formation, but its nature as a clonal neoplasm remains undetermined.
  • Current knowledge is insufficient to definitively classify KS as a sarcoma versus a reactive, virus-driven lesion.